Tivic Health Presents Entolimod Data at TechWatch Meeting
Tivic Health delivered an invited presentation at a TechWatch meeting with the Biomedical Advanced Research and Development Authority on January 26, with select members of the Department of Defense, Defense Threat Reduction Agency, National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases. The company presented key clinical and manufacturing readiness data for Tivic's Toll-like Receptor 5 agonist, Entolimod, underscoring its potential use as a radiation countermeasure, as well as progress on manufacturing readiness that has been accelerated by newly formed subsidiary Velocity Bioworks.TechWatch meetings enable BARDA and other U.S. agencies to evaluate technology and manufacturing readiness and to identify potential pathways for funding and purchasing new technologies. Monday's meeting initiated Tivic's discussions with the agency regarding the potential for incorporating Entolimod into the Strategic National Stockpile, with key stakeholders requesting expedited follow-up. "We appreciate the U.S. government's interest in the differentiated properties of Entolimod compared to the other drugs already stockpiled for treating ARS," said Tivic CEO Jennifer Ernst. "We are fully committed to supporting BARDA and other agencies in their exploration of Entolimod through our upcoming engagements."
Trade with 70% Backtested Accuracy
Analyst Views on TIVC
About TIVC
About the author
Tivic Health Systems Reports FY 2025 Financial Overview
- Rising Operating Expenses: Tivic Health's operating expenses for FY 2025 are projected to reach $7.9 million, significantly up from $4.5 million in 2024, indicating ongoing investments in business expansion and R&D that may pressure short-term profitability.
- Increased Net Loss: The expected net loss for 2025 is between $8.8 million and $9.1 million, compared to $5.7 million in 2024, raising concerns among investors regarding the company's financial health, which could negatively impact stock performance.
- Improved Cash Position: The company anticipates cash and working capital of $12.6 million and $12.4 million in 2025, a substantial increase from $2.0 million in 2024, reflecting positive progress in cash management and liquidity that supports future operations and investments.
- Market Opportunity Outlook: Following its strategic transformation, Tivic Health has identified a $20 billion oncology market opportunity, indicating potential for expansion into new market segments that could lay the groundwork for future growth.
Tivic Health Transforms into Immunotherapy Company
- Strategic Transformation: Under CEO Michael Handley's leadership, Tivic Health has fully pivoted to immunotherapy, focusing on the TLR5 platform with candidates like Entolimod and Entolasta, targeting the oncology supportive care market projected to grow from $15 billion to $20 billion.
- In-House Manufacturing: The company has completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to provide cost efficiencies and a new revenue stream, significantly reducing development timelines and costs for Entolimod while enhancing supply chain control.
- Improved Financial Position: As of December 31, 2025, Tivic's cash and cash equivalents totaled $12.6 million, a substantial increase from $2 million in 2024, indicating improved financial health following new business lines and acquisitions.
- Market Opportunities: Tivic is actively engaging with U.S. government agencies for potential biodefense contracts and plans to initiate clinical trials for Entolimod within the year, showcasing the company's strong potential and readiness in the biotherapeutics market.
TIVIC HEALTH SYSTEMS INC - MAKES PROGRESS ON ENTOLIMOD PLATFORM FOR POSSIBLE FUNDING PARTNERSHIPS
- Advancements in Health Systems: Tivic Health Systems continues to make progress in enhancing its health technology platform.
- Focus on Funding Partnerships: The company is actively seeking potential funding partnerships to support its growth and development initiatives.
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
Tivic Grows Its Intellectual Property Assets
New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.
Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.
Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.
Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.
Tivic Health Scheduled to Announce Third Quarter 2025 Financial Results on November 14th Through Conference Call and Webcast
Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.
Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.
Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.
Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.
Tivic Health Systems Reports FY 2025 Financial Overview
- Rising Operating Expenses: Tivic Health's operating expenses for FY 2025 are projected to reach $7.9 million, significantly up from $4.5 million in 2024, indicating ongoing investments in business expansion and R&D that may pressure short-term profitability.
- Increased Net Loss: The expected net loss for 2025 is between $8.8 million and $9.1 million, compared to $5.7 million in 2024, raising concerns among investors regarding the company's financial health, which could negatively impact stock performance.
- Improved Cash Position: The company anticipates cash and working capital of $12.6 million and $12.4 million in 2025, a substantial increase from $2.0 million in 2024, reflecting positive progress in cash management and liquidity that supports future operations and investments.
- Market Opportunity Outlook: Following its strategic transformation, Tivic Health has identified a $20 billion oncology market opportunity, indicating potential for expansion into new market segments that could lay the groundwork for future growth.
Tivic Health Transforms into Immunotherapy Company
- Strategic Transformation: Under CEO Michael Handley's leadership, Tivic Health has fully pivoted to immunotherapy, focusing on the TLR5 platform with candidates like Entolimod and Entolasta, targeting the oncology supportive care market projected to grow from $15 billion to $20 billion.
- In-House Manufacturing: The company has completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to provide cost efficiencies and a new revenue stream, significantly reducing development timelines and costs for Entolimod while enhancing supply chain control.
- Improved Financial Position: As of December 31, 2025, Tivic's cash and cash equivalents totaled $12.6 million, a substantial increase from $2 million in 2024, indicating improved financial health following new business lines and acquisitions.
- Market Opportunities: Tivic is actively engaging with U.S. government agencies for potential biodefense contracts and plans to initiate clinical trials for Entolimod within the year, showcasing the company's strong potential and readiness in the biotherapeutics market.
TIVIC HEALTH SYSTEMS INC - MAKES PROGRESS ON ENTOLIMOD PLATFORM FOR POSSIBLE FUNDING PARTNERSHIPS
- Advancements in Health Systems: Tivic Health Systems continues to make progress in enhancing its health technology platform.
- Focus on Funding Partnerships: The company is actively seeking potential funding partnerships to support its growth and development initiatives.
Davis Commodities Reports $95M Revenue in H1, Up 42.1%
- Significant Revenue Growth: Davis Commodities Ltd reported a revenue of $95 million for the first half ending June 30, marking a 42.1% increase from $66.9 million a year earlier, indicating strong performance in the agricultural commodity trading sector and boosting market confidence.
- Stock Price Surge: Following the earnings report, Davis Commodities' shares jumped 5.6% to $0.25 in pre-market trading, reflecting investor optimism regarding the company's future growth potential.
- Positive Market Reaction: The stock price increase post-earnings release indicates market recognition of Davis Commodities' performance, which may attract more investor interest and further drive the stock price upward.
- Optimistic Industry Outlook: With the ongoing demand for agricultural commodities, the strong earnings report not only enhances Davis Commodities' market position but also potentially provides funding for future expansion and investments.
Tivic Grows Its Intellectual Property Assets
New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.
Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.
Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.
Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.
Tivic Health Scheduled to Announce Third Quarter 2025 Financial Results on November 14th Through Conference Call and Webcast
Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.
Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.
Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.
Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.
